Skip to main content
  • Vespina Lifesciences Inc.
  • Investment: 2021
  • Status: Active

Vespina Lifesciences Inc. plans to develop to proof-of-concept a potential best-in-class compound with the potential to treat certain types of inflammatory diseases including pulmonary indications with poor therapeutic options as well as non-pulmonary inflammatory diseases. The compound was originally discovered and characterized at Denmark-based Neuprozyme Therapeutics ApS. There are upwards of 70,000 patients newly diagnosed with bronchiectasis in the US every year as more than half of the 16+ million patients diagnosed with COPD in the US likely also have concurrent bronchiectasis. There are no approved treatments that specifically address the underlying mechanism of disease.

Involved Team

Dr. Luc Marengère
Managing Partner
Marc Rivière, MD
General Partner,

Dr. Cynthia Cardinal (CEO)